155 related articles for article (PubMed ID: 31043811)
1. Cost-of-illness study for non-small-cell lung cancer using real-world data.
Seung SJ; Hurry M; Hassan S; Walton RN; Evans WK
Curr Oncol; 2019 Apr; 26(2):102-107. PubMed ID: 31043811
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
3. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
4. Costs of non-small cell lung cancer in the Netherlands.
van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA
Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
6. Changing costs of metastatic non small cell lung cancer in the Netherlands.
Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
8. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
9. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer.
Mahar AL; Coburn NG; Johnson AP
Lung Cancer; 2014 Nov; 86(2):281-7. PubMed ID: 25267166
[TBL] [Abstract][Full Text] [Related]
12. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
[TBL] [Abstract][Full Text] [Related]
13. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
Migliorino MR; Santo A; Romano G; Cortinovis D; Galetta D; Alabiso O; Cartenì G; Vari S; Fasola G; Pazzola A; Giuffrida D; Zaniboni A; Caprioli A; Longo F; Acciai V; de Marinis F
J Cancer Res Clin Oncol; 2017 May; 143(5):783-791. PubMed ID: 28215027
[TBL] [Abstract][Full Text] [Related]
16. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data.
Bremner KE; Krahn MD; Warren JL; Hoch JS; Barrett MJ; Liu N; Barbera L; Yabroff KR
Palliat Med; 2015 Dec; 29(10):918-28. PubMed ID: 26330452
[TBL] [Abstract][Full Text] [Related]
17. The economics of lung cancer management in Canada.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
19. Real-World Treatment Patterns, Survival, and Costs for Ovarian Cancer in Canada: A Retrospective Cohort Study Using Provincial Administrative Data.
Hurry M; Hassan S; Seung SJ; Walton RN; Elnoursi A; McGee JD
J Health Econ Outcomes Res; 2021; 8(2):114-121. PubMed ID: 34993257
[No Abstract] [Full Text] [Related]
20. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
van den Hout WB; Kramer GW; Noordijk EM; Leer JW
J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
